Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Beijing Suncadia Pharmaceuticals Co: Clinical Trials & FDA Approval Profile

Beijing Suncadia Pharmaceuticals Co (Global / Institutional) sponsors 15 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 7 active protocols (4 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)225 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Beijing Suncadia Pharmaceuticals Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)15
Active Pipeline (Recruiting Now)7 (4)
Completed vs Stopped Early8 / 0 (0.0%)
Median Closed Actual Enrollment225 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Beijing Suncadia Pharmaceuticals Co
Hospital Research SiteLocationShared Protocols
Beijing Tiantan Hospital, Capital Medical UniversityBeijing, Beijing Municipality3
The Second Affiliated Hospital Zhejiang University School of MedicineHangzhou, Zhejiang2
Xiangya Hospital Central South UniversityChangsha, Hunan2

Explore interactive annual charts and M&A subsidiary rollups in the Beijing Suncadia Pharmaceuticals Co Interactive Dossier, benchmark peers in Cardiovascular and Thrombosis, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI